Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa
DOI:
https://doi.org/10.2340/000155556397101Abstract
The effect of anti-Parkinson therapy on the urinary excretion of 5-S-cysteinyldopa (5SCD), a catechol metabolite of dihydroxyphenylalanine (DOPA) and marker for the melanocyte, was studied by means of high performance liquid chromatography. 5SCD was normal in Parkinson patients treated with anticholinergics. DOPA administration increased 5SCD excretion. Carbidopa and DOPA together elevated 5SCD markedly in a dose-dependent manner to values higher than seen in some patients with metastatic malignant melanoma. The effect of anti-Parkinson therapy should be considered when using 5SCD as a tumor marker or when a Parkinson patient has a melanoma.Downloads
Download data is not yet available.
Downloads
Published
1983-03-01
How to Cite
Stewart, R., Miller, S., & Gunder, M. (1983). Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa. Acta Dermato-Venereologica, 63(2), 97–101. https://doi.org/10.2340/000155556397101
Issue
Section
Articles
License
LicenseAll digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
